MSD

MK1084 + Pembrolizumab

Biodrugs/ Drugs
Cancer
A Phase 1 Study with MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
1Phase I in Spain